Abstract 46P
Background
The mechanism of PD-1 inhibitors-induced myocarditis in individuals with tumor is still unclear. Regulatory T cells (Treg) can directly inhibit T cell proliferation and activation, and also produce inhibitory cytokines with potent immunosuppressive properties. Deletion or aberrant function of Treg usually leads to autoimmune diseases. But reports on the role of Treg in PD-1 inhibitor-associated myocarditis are still very limited, and its role in the pathogenesis of myocarditis needs to be further explored. In addition, alterations in the composition of the gut microbiota and its metabolites have been shown to be involved in the development of several cardiovascular and autoimmune diseases.
Methods
We first established a melanoma model in mice, which were subsequently divided into three groups: control group, Anti-PD1 group and fecal microbiota removal (FMR) group. The control group and Anti-PD1 group were subcutaneously injected with mouse IgG and PD-1 inhibitors respectively, and FMR group were injected with PD-1 inhibitors subcutaneously along with oral antibiotic antimicrobials to clear the intestinal microbiota. Afterwards, we assessed the severity of myocarditis in mice, performed flow cytometry analysis of immune cells in the heart, determined transcript levels of Treg-related cytokines in the heart, and performed 16S rRNA gene sequence analysis of gut microbiota and correlation analysis of enriched gut microbiota with myocarditis factors.
Results
PD-1 inhibitors induced myocarditis in melanoma mice, leading to a reduction in intracardiac Tregs and downregulation of inflammatory suppressor transcript levels, as well as altering the gut microbial composition of the mice. However, in the presence of gut microbial removal, myocarditis manifestations in the mice described above were attenuated. In addition, microbes enriched in the gut of mice after treatment with PD-1 inhibitors showed a strong correlation with factors associated with the development of myocarditis.
Conclusions
PD-1 inhibitors induced myocarditis and significant reduction of intracardiac Treg in melanoma mice. It is highly likely that alterations in the composition of the gut microbiota due to PD-1 inhibitors played a key role in this process.
Legal entity responsible for the study
The authors.
Funding
Shanxi Provincial Health Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract